Seeking to dampen high prices for new drugs, CVS Caremark plans to allow its clients — such as health plans and employers — to exclude from their formularies any new medicine that has a higher price than a specific threshold for determining value.

Specifically, the pharmacy benefit manager set a threshold of $100,000 per QALY, or quality-of-life years, a benchmark that measures both the quantity and quality of life generated by providing a treatment or some other health care intervention. In the U.S., anywhere from $50,000 to $150,000 is used for gauging value, although $100,000 is commonly used as a threshold.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I guess no one is paying attention again. This is a corporate PR or advertising campaign. It is highly obvious that these corporations have corrupted science. They will merely deceive the public by appearing to be “Cost Saving.” Thanks to the lack of critical thinking occurring here and on most other sites, they will peddle this propaganda. Doing a Cost benefit analysis, sounds a lot like Healthcare rationing to me. Anything is better than looking at the root of the problem here. We need to demand fact based prescription drugs. The government should disband these monopolies, it is to late to fix this. Watch how every medical journalist educated by Pharam will sell this idea as “innovative.”

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy